76
Senescence Accelerated Mouse (SAMP8)
One of several related strains developed from an AKR/J inbred line with a spontaneous accelerated aging phenotype.
77
Tau P301L
MAPT
These transgenic mice overexpress the human Tau-4R/2N isoform bearing the P301L mutation under the control of the neuron-specific murine Thy1 promoter.
Transgenic line expressing mutant human tau under the direction
78
of the mouse prion protein (Prnp) promoter. The transgene Tau P301S MAPT codes for tau with 4 microtubule-binding domains and 1 N(line PS19) terminal insert (4R/1N). PS2APP mice (line B6.152H) x tau mice (line B6.TauP301L). PS2APP were generated by co-injecting two transgenic APP, constructs: human PSEN2 (N141I mutation) and human APP MAPT, (Swedish mutation) driven by the mouse prion promoter and the PSEN2 mouse Thy1 promoter respectively. The transgenic TauP301L mouse (line pR5) expresses the human tau40 isoform driven by the Thy1.2 promoter. MAPT Human 4-repeat tau cDNA with the R406W mutation containing myc and FLAG tags at N-and C-terminal ends, respectively, and driven by the CaMK-II promoter. Human 4-repeat tau driven by the PDGF-β promoter. Tagged with myc and Flag on the N- and C-terminals respectively. Transgenic vector expresses a human N-terminally truncated Aβ sequence (3-42) fused to thyrotropin-releasing hormone. The transgene is under the control of the murine Thy1.2 regulatory sequence. The glutamate at position 3 of Aβ was mutated to glutamine to facilitate pyroglutamate formation by the enzyme glutaminyl cyclase. Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exon
s 1-2.
79
TauPS2APP
80
TAU R406W
81
Tau V337M
MAPT
82
TBA42
APP
83
TetOAPPSweInd (line 102)
APP
84
TetOAPPSweInd (line 107)
APP
Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exons 1-2.
85
TetOAPPSweInd (line 885)
APP
Mouse APP695 with a humanized Aβ region and the Swedish (KM570/571NL) and Indiana (V617F) mutations downstream of a tetracycline-responsive promoter and mouse prion protein exons 1-2.

Regimen Summary of Peptide Medicines for Alzheimer’ Disease (AD) Treatment ---Summarized peptide regimen for in vivo AD study Animal Study Model 3xTg-AD...
第二节 阿尔茨海默病(Alzheimer's disease,AD)阿尔茨海默病(Alzheimer's disease,AD) ,是发生于老年和老年前期、以 进行性认知功能障碍和行为损害为特征的中枢...
Medicines for Alzheimer’ Disease (AD) Treatment ---Summarized peptide regimen for in vivo AD study Animal Study Model 3xTg-AD Transgenic Mice Medicine ?...
阿尔茨海默病(Alzheimer’SDisease,AD)与动力相关蛋白1(dynamin—relatedprotein1,Drp1)_基础医学_医药卫生_专业资料。第3 0卷第 2期 201 3年 4月 生物学...
让我们向江教练致敬,并祝老年痴呆症患者早日康复! 治疗老年痴呆症的小偏方所谓的老年痴呆症,又称阿尔茨海默病(alzheimer's disease,ad)是发生在老年期及老年前期...
b.老年痴呆病 老年性痴呆病,分为阿尔茨海默病(Alzheimer’sdisease,AD)和血管性痴呆(VD) ,是一 种发病于老年期前后的原发性大脑退行性疾病。 近年来老年性痴呆...
老年痴呆症的护理 老年痴呆症又称阿尔茨海默病 (Alzheimer's disease,AD) 是发生在老年期及老年前期的一种 原发性退行性脑病, 指的是一种持续性高级神经功能...
In order to study AD pathology and develop AD ...Using Tg6799 as a mouse model for AD research ...(Alzheimer’s disease,AD)又称老年痴呆症,是一...
Alzheimer's disease 老年痴呆症Alzheimer's disease 老年痴呆症隐藏>> review article Pathways towards and away from Alzheimer’s disease Mark P. Mattson ...
老年痴呆症,又称阿尔茨海默病 (Alzheimer's disease,AD) 是发生在老年期 及老年前期的一种原发性退行性脑病,指 的是一种持续性高级神经功能活动障碍, 即在没...
热门文档